Former Chief Scientific Officer of Alcon Joins GrayBug LLC
06/07/2013

Gerald D. Cagle, Ph.D., Agrees to be a Senior Advisor and Head of Business Development for GrayBug

Online PR News – 07-June-2013 – BALTIMORE, MD (June 7, 2013) – BALTIMORE, MD (June 7, 2013) – GrayBug, LLC, a company developing innovative drug delivery systems and its own drugs to more effectively treat eye disease, announced today that Gerald D. Cagle Ph.D., former Senior Vice President and Chief Scientific Officer at Alcon Laboratories, has joined GrayBug as a senior advisor and head of business development.

I am very excited to be joining the Graybug team and look forward to being involved in the progression of their novel drug delivery technology to market.

“GrayBug is at the forefront of innovative drug delivery strategies for ocular diseases and has the potential to significantly advance the ophthalmic industry with its unique sustained release technology,” said Dr. Cagle. “I am very excited to be joining the Graybug team and look forward to being involved in the progression of their novel drug delivery technology to market.”

Dr. Cagle is a highly respected pharmaceutical executive with managerial, technical and business experience spanning over 35 years. Dr. Cagle served in key leadership roles for Alcon Laboratories Inc., including positions as a laboratory scientist, followed by service in clinical research, regulatory affairs, and product development. During the last 13 years at Alcon, he held the position of Senior Vice President and Chief Scientific Officer. While at Alcon, Dr. Cagle either directed or was a contributing author of numerous new drug applications (NDAs) and premarket approvals (PMAs), from which more than 100 new Alcon products were achieved.

About GrayBug
GrayBug® is developing proprietary controlled release technologies and its own drugs for ophthalmic pharmaceutical indications. The company’s lead product is a polymer-drug biomolecular conjugate for the treatment of neovascular diseases, including age-related macular degeneration (AMD). GrayBug also has a proprietary platform technology that allows sustained drug delivery into various compartments of the eye while minimizing inflammation common with current controlled release technologies injected into the eye. These technologies were co-developed by GrayBug founder, Justin Hanes, Ph.D., who is the Lewis J. Ort Professor of Ophthalmology at the Wilmer Eye Institute of the Johns Hopkins University, in collaboration with GrayBug cofounders, and top ophthalmology clinician-scientists from the Wilmer Eye Institute, Dr. Peter Campochiaro and Dr. Peter J. McDonnell. For more information, please visit www.graybug.com.

visit our website